CRISPR Therapeutics (CRSP) Highlights Strategic Priorities and 2024 Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. HUM
2. SPCX
3. ALHC
4. TMUS
5. PEP
6. AXP
7. T
8. SPY
9. CVS
10. UNH

Go back to CRISPR Therapeutics (CRSP) Highlights Strategic Priorities and 2024 Outlook

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

January 8, 2024 7:00 AM EST

ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.

We had a landmark year in 2023, marked by the first-ever approval of a CRISPR-based gene-editing therapy in addition to entering the clinic with our in vivo therapies, said Samarth Kulkarni, Ph.D., Chairman and Chief Executive Officer of CRISPR Therapeutics. As we look ahead to 2024, we... More